Publication:
Development of Hyperprolactinemia Induced by the Addition of Bupropion to Venlafaxine XR Treatment

Thumbnail Image

Organizational Units

Program

Authors

KILIÇ, Alperen
Ozturk, AHMET
Deveci, ERDEM
Kirpinar, Ismet

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Hyperprolactinemia is characterized by abnormally increased serum prolactin levels. Menstrual irregularities and hyperprolactinemia can be caused by a variety of medical conditions as well as due to the use of some psychopharmacological drugs, namely antipsychotics; it can also develop during antidepressant treatment. Bupropion is an antidepressant functioning via the inhibition of noradrenaline and dopamine reuptake. The endocrine and sexual adverse events of this agent are rare. In the literature, only one case reporting hyperprolactinemia or galactorrhea caused by bupropion use is available. Here, we present the case of a patient diagnosed with depressive disorder and receiving venlafaxine, who developed hyperprolactinemia and oligomenorrhea after the addition of bupropion the ongoing treatment and showed serum prolactin levels decreased to normal ranges shortly after the discontinuation of bupropion.

Description

Source:

Keywords:

Keywords

Citation

KILIÇ A., Ozturk A., Deveci E., Kirpinar I., -Development of Hyperprolactinemia Induced by the Addition of Bupropion to Venlafaxine XR Treatment-, BEZMIALEM SCIENCE, cilt.6, ss.150-152, 2018

Endorsement

Review

Supplemented By

Referenced By

3

Views

10

Downloads


Sustainable Development Goals